Growth Metrics

Esperion Therapeutics (ESPR) Depreciation & Amortization (CF) (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Depreciation & Amortization (CF) readings, the most recent being $21000.0 for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 22.22% to $21000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $100000.0, a 58.73% increase, with the full-year FY2025 number at $100000.0, up 58.73% from a year prior.
  • Depreciation & Amortization (CF) hit $21000.0 in Q4 2025 for Esperion Therapeutics, down from $26000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $153000.0 in Q1 2021 to a low of $6000.0 in Q4 2023.
  • Median Depreciation & Amortization (CF) over the past 5 years was $51000.0 (2023), compared with a mean of $75736.8.
  • Biggest five-year swings in Depreciation & Amortization (CF): plummeted 93.48% in 2023 and later skyrocketed 350.0% in 2024.
  • Esperion Therapeutics' Depreciation & Amortization (CF) stood at $153000.0 in 2021, then crashed by 39.87% to $92000.0 in 2022, then plummeted by 93.48% to $6000.0 in 2023, then skyrocketed by 350.0% to $27000.0 in 2024, then dropped by 22.22% to $21000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $21000.0 (Q4 2025), $26000.0 (Q3 2025), and $27000.0 (Q2 2025) per Business Quant data.